Prospective evaluation on the effects of multidisciplinary intervention on physical functions in the patients with cancer cachexia

Prospective evaluation on the effects of multidisciplinary intervention on physical functions in the patients with cancer cachexia - anamorelin prospective study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046454

Enrollment

Registered

2021-12-24

Start date

2022-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer/ colorectal cancer/ pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a. Patients who are eligible for administration of anamorelin b. Patients who have obtained the written consent of the patient or his/her substitute to participate in the study

Exclusion criteria

Exclusion criteria: a. Patients with contraindications to the administration of anamorelin b. Patients who are judged by the attending physician, or the department or facility to which the attending physician belongs, to be undesirable to participate in the study.

Design outcomes

Primary

Measure	Time frame
Improvement in physical functions after 12 weeks of anamorelin administration	—

Secondary

Measure	Time frame
change from baseline in dietary intake, ECOG performance status(PS),lean body mass(LBM),total weight,physical functions, physical function's satisfaction,adverse events,overall survival(OS),duration of treatment, progression-free survival(PFS),objective response rateand(ORR),disease control rate(DCR),efficacy,safety,predictive factors for treatment efficacy and safety in patirnts with gastric/colorectal/pancreatic cancer by early induction of multimodel care with anamorelin administration,nutritional and excercise at each assessment period.	—

Measure

Time frame

change from baseline in dietary intake, ECOG performance status(PS),lean body mass(LBM),total weight,physical functions, physical function's satisfaction,adverse events,overall survival(OS),duration of treatment, progression-free survival(PFS),objective response rateand(ORR),disease control rate(DCR),efficacy,safety,predictive factors for treatment efficacy and safety in patirnts with gastric/colorectal/pancreatic cancer by early induction of multimodel care with anamorelin administration,nutritional and excercise at each assessment period.

—

Countries

Japan

Contacts

Public Contactyuka aimono

Hitachi General Hospital Department of pharmacy

yuka.aimono.cp@hitachi.com0294-23-1111

Outcome results